Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. (Delaware) covers events reported on July 6, 2015. The company is based in Melville, New York, and the report details corporate governance actions approved by the Board of Directors pursuant to stockholder authority.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on capital structure adjustments rather than operational financial performance.
Material Changes
- Reverse Stock Split: A 1-for-20 reverse split of issued and outstanding common stock was approved, effective at the opening of business on July 7, 2015.
- Authorized Shares Reduction: The number of authorized common shares was reduced from 200,000,000 to 30,000,000.
- Regulatory Filing: A Certificate of Amendment was filed with the Delaware Secretary of State to effectuate these changes.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors beyond the structural changes noted. The company issued a press release on July 6, 2015, to announce these events, which is included as an exhibit.
Investor Verification Checklist
- Verify the effective date of the 1-for-20 reverse split (July 7, 2015) and its impact on share count and price.
- Confirm the new authorized share cap of 30,000,000 shares.
- Review the attached Certificate of Amendment (Exhibit 3.1) for specific legal terms.
- Check the press release (Exhibit 99.1) for additional context on the rationale for the split.